

TTKHC:SECL:GJ:020:19

January 30, 2019

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 001 National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra East Mumbai 400 051

SCRIP CODE:

507747

SCRIP CODE:

**TTKHLTCARE** 

Dear Sirs,

Re: Unaudited Financial Results along with Limited Review Report for the Quarter and Period ended 31st December, 2018 (Standalone)

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the Quarter and Period ended 31st December, 2018 (Standalone), duly reviewed by the Audit Committee and approved by the Board of Directors of the Company at their Meeting held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully

For TTK Healthcare Limited

Keek away

(S KALYANARAMAN)

Director & Wholetime Secretary

Encl.: a/a

CIN: L24231TN1958PLC003647



### TTK HEALTHCARE LIMITED

Regd. Office: No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2018 (STANDALONE)

[Prepared in compliance with the Indian Accounting Standards (Ind AS)] (Rs. in lakhs) Year to date figures for For the Year For the Quarter ended SI. the period ended ended **Particulars** (31/12/2018) (30/09/2018) (31/12/2017) (31/12/2018) (31/12/2017) (31/03/2018) No. Unaudited Unaudited Unaudited Unaudited Unaudited Audited Revenue from Operations 14.904.69 16.609.78 14.599.56 48.827.57 43,243.95 57,754.65 11. Other Income 174.05 189.77 179.58 547.17 526.35 757.47 III. Total Income (I + II) 15,078.74 16,799.55 14,779.14 49,374.74 43,770.30 58,512.12 IV Expenses (a) Cost of materials consumed 2 693 99 2,790.63 2,233.80 7,773.76 6,167.80 8.713.56 (b) Purchase of Stock-in-trade 3.674.70 4.560.03 15,437.58 3,948.96 12,878.40 11,816.52 Changes in inventories of Finished Goods, Work-in-progress (26.02)(467.43)(365.30)(367.69)(235.51)8.20 and Stock-in-trade Employee benefits expense 3.100.81 3.320.42 (d) 2.714.11 9.816.94 8.390.74 12.011.55 Finance Costs (e) 69 93 94 14 142.53 269 00 376.83 472.93 Depreciation and Amortization Expense (f) 346.88 347.66 376.56 1,058.36 1,161.33 1,524.22 (g) Other Expenses 4,416.16 5,057.46 4,157.92 14,751.55 14,443.05 17.329.37 Total Expenses (IV) 14,276.45 15,702.91 13,208.58 46,180.32 42,120.76 55,497.41 ٧. Profit / (Loss) before Exceptional Items and Tax (III - IV) 802.29 1,096.64 1,570.56 3,014.71 3,194.42 1,649.54 VI. Exceptional Items VII. Profit / (Loss) before Tax (V - VI) 802.29 1.096.64 1,570.56 3.194.42 1,649.54 3,014.71 VIII Tax Expense: (1) Current Tax 290.00 400.00 376.00 1,180.00 680.00 1,125.00 (2) Deferred Tax 24.02 30.80 (30.27)72 51 (47.82)73.18 IX. Profit / (Loss) for the period from Continuing Operations (VII-488.27 665.84 1,224.83 1,941.91 1.017.36 1,816.53 Profit / (Loss) from Discontinued Operations Tax Expense of Discontinued Operations ΧI XII. Profit / (Loss) from Discontinued Operations (after tax) (X -XI) XIII. Profit / (Loss) for the period (IX + XII) 488.27 665.84 1,224.83 1,941.91 1.017.36 1.816.53 XIV Other Comprehensive Income: Items that will not be reclassified subsequently to profit or (A) (i) 86.66 166.81 215 62 194 99 269.44 104.65 loss (ii) Income tax relating to items that will not be reclassified to (21.22)profit or loss (B) (i) Items that will be reclassified to profit or loss Income tax relating to items that will be reclassified to profit or loss Total Comprehensive Income for the period (XIII + XIV) XV. [Comprising Profit / (Loss) and Other Comprehensive Income 655.08 752.50 1.440.45 2,136.90 1.286.80 1,899.96 for the period] Paid-up Equity Share Capital (Face Value Rs.10 per share) 1,413.03 1,413.03 776.60 1,413.03 776.60 1.413.03 Other Equity as per Balance Sheet of previous accounting year 21,884.41 XVI. Earnings per Equity Share (For Continuing Operations): (1) Basic (in Rs.) 3.46 4.71 15.77 13.74 13 10 12.86 (2) Diluted (in Rs.) 3.46 4.71 13.74 15.77 13.10 12.86 XVII. Earnings per Equity Share (For Discontinued Operations): (1) Basic (in Rs.) (2) Diluted (in Rs.) XVIII. Earnings per Equity Share (For Continuing and Discontinued Operations): (1) Basic (in Rs.) 15 77 13 74 13 10 12.86 3 46 4.71 (2) Diluted (in Rs.) 3.46 4.71 15.77 13.74 13.10 12.86

### Notes:

- (1) The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 30th January, 2019 at Chennai.
- (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (3) The EPS for the Third Quarter and Nine-month period ended 31st December, 2017 was reckoned on the basis of the then existing Share Capital without taking into account 63,64,350 Equity Shares of Rs.10 each allotted to the Shareholders of the erstwhile TTK Protective Devices Limited that got amalgamated with the Company pursuant to the sanction received from the National Company Law Tribunal (NCLT) in December, 2017. If these shares are considered, the EPS would have been Rs.8.67 and Rs.7.20 for the Quarter and Nine-month period ended 31st December, 2017, respectively.
- (4) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's presentation.
- (5) This Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK Healthcare Limited

Place:

Chennai

Date: January 30, 2019

T T RAGHUNATHAN
EXECUTIVE VICE CHAIRMAN



# TTK HEALTHCARE LIMITED

Regd. Office: No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2018

SI.	Partition 1	For	the Quarter e		Year to date figures for the period ended		(Rs. in lakhs) For the Year ended	
No.	Particulars		(31/12/2018)	(30/09/2018)	(31/12/2017)	(31/12/2018)	(31/12/2017)	(31/03/2018)
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	-	ment Revenue: les and Other Operating Income)						
	(a)	Pharmaceuticals	5,272.28	5,916.44	5,240.71	16,742.35	14,562.57	19,233.47
	(b)	Consumer Products	4,140.43	4,708.29	4,288.62	15,107.72	14,585.73	18,429.1
	(c)	Medical Devices	1,040.77	1,038.19	824.91	3,212.76	2,329.20	3,265.18
	(d)	Protective Devices	2,596.09	2,937.40	2,612.60	8,283.44	6,659.06	10,066.98
	(e)	Foods	1,842.32	1,997.37	1,622.67	5,435.22	5,061.35	6,701.0
	(f)	Others	12.80	12.09	10.05	46.08	46.04	58.8
	Tota	al	14,904.69	16,609.78	14,599.56	48,827.57	43,243.95	57,754.6
	Les	s : Inter Segment Revenue	-		-	<del>-</del>	-	-
	Net	Sales / Income from Operations	14,904.69	16,609.78	14,599.56	48,827.57	43,243.95	57,754.6
2.	[Pro	ment Results: offit (+) / Loss (-) before tax and interest from each ment]						
	(a)	Pharmaceuticals	422.97	732.53	563.25	1,579.52	1,037.03	1,323.86
	(b)	Consumer Products	900.49	821.02	1,086.91	2,851.51	2,074.38	2,871.16
	(c)	Medical Devices	199.67	222.80	175.06	697.48	473.01	765.70
	(d)	Protective Devices	(119.21)	(165.01)	340.77	(289.39)	(260.01)	206.9
	(e)	Foods	(291.35)	(137.98)	(186.23)	(606.46)	(524.87)	(728.67
	(f)	Others	8.88	5.64	1.94	25.20	12.41	17.1
	Tota	al	1,121.45	1,479.00	1,981.70	4,257.86	2,811.95	4,456.1
	Les	s : Finance Cost	69.93	94.14	142.53	269.00	376.83	472.9
	Les	s: Unallocable Expenses (Net of Unallocable Income)	249.23	288.22	268.61	794.44	785.58	968.52
	Tota	al Profit (+) / Loss (-) before tax	802.29	1,096.64	1,570.56	3,194.42	1,649.54	3,014.7
			As on 31/12/2018	As on 30/09/2018	As on 31/12/2017	As on 31/12/2018	As on 31/12/2017	As on 31/03/2018
3.	Sea	ment Assets	31/12/2010	30/03/2010	31/12/2017	31/12/2010	31/12/2017	31/03/2010
55.00	(a)	Pharmaceuticals	5,214.23	5,635.26	4,830.49	5,214.23	4,830.49	4,356.8
	(b)	Consumer Products	2,851.81	3,335.11	2,863.57	2,851.81	2,863.57	2,603.78
	(c)	Medical Devices	4,174.09	3,879.95	3,091.95	4,174.09	3,091.95	3,061.00
	(d)	Protective Devices	8,571.20	8,666.24	11,123.90	8,571.20	11,123.90	11,190.00
	(e)	Foods	9,330.35	9,645.43	9,956.07	9,330.35	9,956.07	9.815.26
	(f)	Others	107.31	93.31	77.09	107.31	77.09	75.44
	Tota		30,248.99	31,255.30	31,943.07	30,248.99	31,943.07	31,102.38
		llocated	14,472.42	13,800.95	12,587.35	14,472.42	12,587.35	12,166.78
	-	al Assets	44,721.41	45,056.25	44,530.42	44,721.41	44,530.42	43,269.16
4.		ment Liabilities	44,721.41	40,000.20	44,330.42	44,721.41	44,550.42	43,203.10
	(a)	Pharmaceuticals	4,662.16	5,006.86	4,497.07	4,662.16	4,497.07	3,829.48
	(b)	Consumer Products	4,369.94	4,999.14	4,222.28	4,369.94	4,222.28	4,247.11
		Medical Devices	1,018.23	919.14	1,139.31	1,018.23	1,139.31	769.33
		Protective Devices	2,200.21	2,245.02	2,504.78	2,200.21	2,504.78	2,531.04
	(e)	Foods	1,014.46	1,072.35	840.56	1,014.46	840.56	867.2
			138.65	137.43	138.95	138.65	138.95	136.1
	(f)	Others					13,342.95	12,380.37
	Tota		13,403.65	14,379.94	13,342.95	13,403.65	13,342.95	12,300.3
	Unal	llocated	5,505.84	5,223.37	4,559.92	5,505.84	4,559.92	4,333.36

### Notes:

- Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.
- 2. Details of products included in each of the Segments are as below:
  - Pharmaceuticals include products for both Human and Veterinary use.
  - Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
  - Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
  - Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
  - · Foods comprise manufacturing and marketing of Food Products.
  - "Others" include Printing and Publishing of Maps and Atlases.
- The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.
- 4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's presentation.

FOR TTK HEALTHCARE LIMITED

Place: Chennai

Date: January 30, 2019

T T RAGHUNATHAN
EXECUTIVE VICE CHAIRMAN



### TTK HEALTHCARE LIMITED

Regd. Office: No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

### EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 31ST DECEMBER, 2018 (STANDALONE)

							(Rs. in lakhs)
SI.	Particulars	For the Quarter ended			Year to date figures for the period ended		For the Year ended
No.		(31/12/2018)	(30/09/2018)	(31/12/2017)	(31/12/2018)	(31/12/2017)	(31/03/2018)
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1.	Total income from Operations	14,904.69	16,609.78	14,599.56	48,827.57	43,243.95	57,754.65
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	802.29	1,096.64	1,570.56	3,194.42	1,649.54	3,014.71
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	802.29	1,096.64	1,570.56	3,194.42	1,649.54	3,014.71
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	488.27	665.84	1,224.83	1,941.91	1,017.36	1,816.53
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]		752.50	1,440.45	2,136.90	1,286.80	1,899.96
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	776.60	1,413.03	776.60.	1,413.03
7.	Other Equity as per the Balance Sheet of previous accounting year						21,884.41
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
	(a) Basic (in Rs.)	3.46	4.71	15.77	13.74	13.10	12.86
	(b) Diluted (in Rs.)	3.46	4.71	15.77	13.74	13.10	12.86

### Notes:

- (1) The above is an extract of the detailed Statement of Unaudited Financial Results for the Third Quarter and period ended 31st December, 2018, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (2) The full financial results for the Third Quarter ended 31st December, 2018 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).
- (3) These financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their Meeting held on 30th January, 2019 at Chennai.
- (4) The Statutory Auditors of the Company have carried out Limited Review of the Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- (5) The EPS for the Third Quarter and Nine-month period ended 31st December, 2017 was reckoned on the basis of the then existing Share Capital without taking into account 63,64,350 Equity Shares of Rs.10 each allotted to the Shareholders of the erstwhile TTK Protective Devices Limited that got amalgamated with the Company pursuant to the sanction received from the National Company Law Tribunal (NCLT) in December, 2017. If these shares are considered, the EPS would have been Rs.8.67 and Rs.7.20 for the Quarter and Nine-month period ended 31st December, 2017, respectively.
- (6) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's presentation.

For TTK HEALTHOARE LIMITED

Place: Chennai

Date: January 30, 2019

T T RAGHUNATHAN
EXECUTIVE VICE CHAIRMAN

### **PKF SRIDHAR & SANTHANAM LLP**

Chartered Accountants

# Independent Auditor's Review Report on review of Interim financial results

# To the Board of Directors of TTK Healthcare Limited

We have reviewed the Unaudited financial results of TTK Healthcare Limited ("the Company") for the quarter and period ended 31st December 2018 which are included in the accompanying 'Financial Results for the quarter and period ended 31st December 2018 together with the notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 which has been initialed by us for identification purposes.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

### Conclusion:

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm's Registration No. 003990S/S200018

S. Rajeshwari

Partner

Membership No. 024105

Place: Chennai

Date: 30th January 2019